Effects of oral administration of anti-inflammatory medications on inhibition of paracentesis-induced blood-aqueous barrier breakdown in clinically normal cats.
OBJECTIVE
To assess inhibitory effects of orally administered anti-inflammatory medications on paracentesis-induced intraocular inflammation in clinically normal cats.


METHODS
30 clinically normal domestic shorthair cats.


METHODS
Cats were randomly assigned to a control group and 4 treatment groups. Cats in the treatment groups received an anti-inflammatory medication orally once daily at 7 AM (acetylsalicylic acid [40.5 mg/cat], meloxicam [0.1 mg/kg], prednisone [5 mg/cat], or prednisolone [5 mg/cat]) for 5 days beginning 2 days before paracentesis-induced breakdown of the blood-aqueous barrier (BAB) and continuing until 2 days after paracentesis. Paracentesis of the anterior chamber was performed in 1 randomly selected eye of each cat. Fluorophotometry was performed in both eyes of each cat immediately before (time 0) and 6, 24, and 48 hours after paracentesis.


RESULTS
At 24 and 48 hours after paracentesis, fluorescein concentration in the eye subjected to paracentesis in the cats receiving prednisolone was decreased, compared with that in the control cats. At 48 hours, a decrease in the fluorescein concentration was also apparent in the eye subjected to paracentesis in the cats receiving meloxicam, compared with that in the control cats. There was no evidence of treatment effects for acetylsalicylic acid or prednisone. There was no evidence of treatment effects in eyes not subjected to paracentesis.


CONCLUSIONS
Orally administered prednisolone and meloxicam significantly decreased intraocular inflammation in clinically normal cats with paracentesis-induced BAB breakdown. Oral administration of prednisolone or meloxicam may be an effective treatment for cats with uveitis.
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA. arankin@vet.k-state.edu
Amy J
AJ
Rankin
Lionel
L
Sebbag
Nora M
NM
Bello
William R
WR
Crumley
Rachel A
RA
Allbaugh
D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D018916:Blood-Aqueous Barrier; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D003287:Contrast Media / Q000378:metabolism; D005123:Eye / Q000187:drug effects*; D005260:Female; D019793:Fluorescein / Q000378:metabolism; D015590:Fluorophotometry / Q000662:veterinary; D008297:Male; D019152:Paracentesis / Q000379:methods*; D014605:Uveitis / Q000662:veterinary*
D000893:Anti-Inflammatory Agents; D003287:Contrast Media; D019793:Fluorescein